DEF 14A: Black Diamond Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Proposes Officer Liability Amendment

Black Diamond Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, auditor ratification, and an amendment to limit officer liability.

Summary

• Black Diamond Therapeutics will hold its 2024 Annual Meeting of Stockholders online on June 6, 2024, at 9:00 a.m. Eastern Time.
• Stockholders of record as of April 9, 2024, are entitled to vote.
• The meeting will address the election of two Class I directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm for the fiscal year ending December 31, 2024, and approval of an amendment to the company's certificate of incorporation to limit the liability of certain officers.
• The board recommends voting FOR the election of Prakash Raman and Mark A. Velleca as Class I directors, FOR the ratification of PricewaterhouseCoopers LLP, and FOR the approval of the officer liability amendment.
• The company is providing proxy materials online, with a Notice of Availability mailed to stockholders on or about April 24, 2024.
• Stockholders can vote online, by telephone, or by mail before the meeting, or electronically during the virtual meeting.
• The company had 52,530,334 shares of common stock outstanding as of April 9, 2024.
• The board of directors consists of eight members divided into three classes with staggered three-year terms.
• The company incurred $729,000 in audit fees from PricewaterhouseCoopers LLP for the fiscal year 2023.
• The proposed amendment to the certificate of incorporation would add Article X to adopt amended DGCL Section 102(b)(7), extending exculpation protection to officers.
• The affirmative vote of holders of a majority of the shares outstanding and entitled to vote as of the record date is required to approve the Exculpation Amendment.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting routine corporate governance matters. The proposed amendment to limit officer liability could be viewed positively by management and potential executives, but it also carries a slight risk of reduced accountability. Overall, the sentiment is neutral to slightly positive.

Positives

• The company is taking advantage of SEC rules to distribute proxy materials online, reducing environmental impact and costs.
• The virtual-only meeting format enhances stockholder access and participation.
• The proposed amendment to limit officer liability could attract and retain executive talent.
• The board of directors believes that limiting concern about personal liability will empower officers to best exercise their business judgment in furtherance of stockholder interests without the distraction of potentially being subject to claims following actions taken in good faith.
• The company has a compensation recovery policy in place.

Negatives

• Stockholders cannot attend the Annual Meeting in person.
• The proposed amendment to limit officer liability could potentially reduce accountability for certain officer actions, although it does not eliminate liability for breaches of loyalty, bad faith actions, or improper personal benefits.

Risks

• If the stockholders do not ratify the appointment of PricewaterhouseCoopers LLP, the audit committee will reconsider whether to retain PwC.
• The company's ability to attract and retain highly qualified officer candidates may be adversely impacted if it does not implement the expanded protections now offered under Delaware law.
• The nature of the role of directors and officers often requires them to make decisions on crucial matters, which can create substantial risk of investigations, claims, actions, suits, or proceedings seeking to impose liability on the basis of hindsight, especially in the current litigious environment and regardless of merit.

Future Outlook

The company intends to comply with future requirements to the extent they become applicable.

Management Comments

• Our board of directors believes the proposed Exculpation Amendment would better position the Company to attract top officer candidates, retain our current officers and enable our officers to exercise their business judgment in furtherance of the interests of the stockholders without the potential for distraction posed by the risk of personal liability.
• Additionally, it would align the protections for our officers with those protections currently afforded to our directors.

Industry Context

Many public companies are updating their governing documents to align with amended Section 102(b)(7) of the DGCL, and we expect this practice to continue.

Comparison to Industry Standards

• The corporate law codes of several other states already permit corporations to exculpate officers in a similar manner to Section 102(b)(7).
• Other public companies have updated their governing documents to align with amended Section 102(b)(7) of the DGCL, and we expect this practice to continue.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into a consulting agreement with KAPital Consulting, LLC, pursuant to which Dr. Dhingra provides certain consulting, advisory and other mutually agreed upon services to the Company from time to time, not to exceed eight (8) days per year.
• In each fiscal year 2022 and 2023, the Company paid $50,000 to Dr. Dhingra in consideration for the services provided to the Company pursuant to the Consulting Agreement.
• In July 2023, New Enterprise Associates purchased 1,000,000 shares of common stock in our registered public offering for $5,000,000.
• In July 2023, RA Capital Management L.P. purchased 935,850 shares of common stock in our registered public offering for $4,679,250.

Stakeholder Impact

• Shareholders are asked to vote on key corporate governance matters.
• Employees may be affected by the proposed amendment to limit officer liability, potentially influencing the company's ability to attract and retain executive talent.
• The outcome of the proposals could impact the company's strategic direction and long-term performance, affecting all stakeholders.

Next Steps

• Stockholders should vote on the proposals before the deadlines.
• The company will file the Certificate of Amendment with the Secretary of State of the State of Delaware promptly after the Annual Meeting if the proposed Exculpation Amendment is approved by our stockholders.
• The company plans to announce preliminary voting results at the Annual Meeting and will publish final results in a Current Report on Form 8-K, or Form 8-K, to be filed with the SEC within four business days following the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Officer Liability, PricewaterhouseCoopers, Corporate Governance, Stockholders, Black Diamond Therapeutics